Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

ukemia/small lymphocytic lymphoma, relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The clinical development program currently includes 30 clinical trials, including six Phase 3 trials. Details about the complete ibrutinib clinical program is posted on clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has two product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3ResMed To Announce Second Quarter 2015 Results 2
... Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today ... credit facilities of its wholly owned subsidiary Valeant ... by the Company.  The proposed $1.7 billion senior ... a $200 million revolving facility and a $1.5 ...
... 20, 2011 – Ingenuity® Systems, a leading ... life science researchers, today announced the addition ... from miRecords , plus thousands of ... peer-reviewed literature. The newly added content supplements ...
Cached Medicine Technology:Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2Ingenuity Announces New Additional MicroRNA Content to Complement First-of-its-Kind MicroRNA Filtering Capability in IPA 2
(Date:12/21/2014)... 2014 In this report, the ... power source, product, and application. The market, by ... pneumatic instruments. By product, the market covers the ... The handpieces market is further subdivided into drills, ... laparoscopic instruments, shavers, wire/pin drivers, and others. Moreover, ...
(Date:12/21/2014)... Ca (PRWEB) December 21, 2014 Khanna ... was a guest at the Aspen Helicopters holiday event ... and a Santa with sleigh, flown by an aspen ... appeared invisible; only Santa with sleigh was visible.(please see ... day and night. Dr.Khanna has helped many pilots with ...
(Date:12/21/2014)... Thompson HealthDay Reporter FRIDAY, ... e-cigarettes less addictive than traditional cigarettes, new research finds. ... did regular cigarettes, thousands of ex-smokers said they have fewer ... over their need to smoke, researchers reported. ... less for e-cig use than for tobacco use," said lead ...
(Date:12/21/2014)... 21, 2014 Serious Buyer, Andrew Hawley ... Jm Morrison and the Doors International Ballroom at the ... also be the only time that Morrison's mother would ... Nov. 25, 1967. According to Hawley, “This would be ... play the Alexandria Roller Rink earlier that year and ...
(Date:12/21/2014)... December 21, 2014 Theme ... a new intro plugin for Final Cut Pro X ... videos, logos, and more with absolute ease.” Said Christiana ... users the tools needed to easily animate their media ... Cut Pro X users to animate pictures, videos, logos, ...
Breaking Medicine News(10 mins):Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... all set to shock parents of modest means and desirous ... in Karnataka where the fee of private medical colleges is ... the Fee Fixation Committee headed by Justice H Rangavittalachar, which ... fuming.,The college which quoted the highest annual fee of Rs ...
... The health of UK's sex workers will be adversely affected ... seeks to improve the quality of life of the people ... commercial sex exploitation, and also challenge the opinion that street ... degree of policing in red light areas, which may also ...
... of Veterinary Medicine has developed cancer vaccine for the ... worked in collaboration with the oncologist from Arizona, California, ... very efficient in preventing the death of the animal, ... treatment. Ilene Kurzman, a researcher in the veterinary ...
... Prince of Wales said that there is an increase in ... to balance their lifestyle and exercise regularly. ,He ... are// following the close behind the United States in the ... infrastructure of the city discourages pedestrians and physical activity. ...
... the University of Manchester have evolved a method to diagnose ... detect chemical warfare agents. Dr Paul Thomas led a team ... explosives at the airports. // ,The ... is now being used by researchers to detect "unhealthy" molecules ...
... and his colleagues have reported in the Cochrane Database ... genital tract reduces// the surgical procedure such as Episiotomy ... surgical procedure done in the perineum in the area ... involved during birthing process to expand the opening of ...
Cached Medicine News:Health News:Sensor Can Detect "Unhealthy" Molecules In Breath 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: